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The  activity of the  avian myeloblastosis virus (AMV) 
or  the human immunodeficiency virus type 1 (HIV-1) 
protease on peptide substrates which represent cleav- 
age  sites found in the gag and gag-pol polyproteins of 
Rous sarcoma  virus (RSV) and HIV-1 has been ana- 
lyzed. Each protease efficiently processed cleavage site 
substrates found in their cognate polyprotein precur- 
sors. Additionally, in some instances heterologous ac- 
tivity  was detected. The  catalytic efficiency of the RSV 
protease on cognate substrates  varied by as much as 
30-fold. The  least  efficiently processed substrate, p2- 
p10,  represents  the  cleavage  site between the RSV p2 
and  p10  proteins.  This peptide was  inhibitory to the 
AMV as well as the HIV- 1 and HIV-2 protease cleavage 
of other  substrate peptides with Ki values in  the 5-20 
I . ~ M  range. Molecular modeling of the RSV protease 
with  the  p2-p10 peptide docked in the  substrate bind- 
ing pocket and  analysis of a series of single-amino acid- 
substituted p2-p10 peptide analogues suggested that 
this peptide is  inhibitory because of the  potential of a 
serine residue in the P1' position to  interact  with one 
of the catalytic aspartic acid residues. To open the 
binding pocket and allow rotational freedom for  the 
serine  in Pl', there  is a further requirement  for  either 
a glycine or a polar  residue in P2' and/or  a  large amino 
acid residue in P3'. The amino acid residues in Pl-P4 
provide  interactions  for  tight  binding of the peptide in 
the  substrate  binding pocket. 
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Translation of avian  retrovirus genomic RNA  results in the 
production of two polyprotein precursors, Pr76gaK and 
Pr180g"gp01. Pr76Kag encodes the  structural  proteins required 
for virus  particle assembly  including the MA,' p2, p10, CA, 
NC, and  PR  proteins,  listed  in  order from the  amino-terminal 
end of the precursor. MA is responsible  for the  attachment of 
polyprotein precursors to the cell membrane (1) and forms 
the  matrix between the lipoprotein envelope and  the  inner 
capsid core of the  virus  particle (2). It  can also bind weakly 
to  viral  RNA (3,4).  The p2 and p10 proteins have no known 
function. CA forms  the  inner capsid core of the  particle ( 5 ) ,  
and  NC  is required for packaging of viral specific RNA  in  the 
nucleoprotein  core (6, 7). Protease is responsible  for the 
processing of the Pr76gag and Pr180g"g-P01 polyprotein precur- 
sors (8). Pr180g"g-P"1 contains reverse transcriptase  and  inte- 
grase, in  addition  to gag-encoded structural  proteins. 
The  protease-dependent process of cleavage of the gag and 
pol polyproteins releases the  mature  forms of the  structural 
and  enzymatic  proteins required  for retrovirus replication ( 5 ) .  
This  maturation process appears  to be regulated both  spatially 
and temporally.  Activation of the  protease  appears  to occur 
in  nascent  virus  particles with  processing  occurring  normally 
either coincident with virus particle assembly at the cell 
membrane  or soon after  budding of virus particles. Loss of 
protease  activity  results  in  the  production of immature,  non- 
infectious virus (9-11). Since  protease  activity  is required for 
the  production of infectious  virus, this enzyme is a target for 
the design of antiviral  agents. 
We have compared  the  activity of the AMV and  HIV-1  PRs 
on  peptide  substrates  representing cleavage sites found in  the 
RSV and  HIV-1 polyprotein  precursors. We have  identified  a 
peptide  corresponding  to a cleavage site  present  in  the  amino- 
terminal region of the RSV  polyprotein precursor, which acts 
both as a weak substrate for the AMV PR  and  an effective 
competitive inhibitor of AMV, HIV-1, and  HIV-2  PRs.  In  this 
report, we propose  a mechanism for inhibition of the AMV 
PR by this RSV  gag  p2-plO  cleavage-site  peptide. 
EXPERIMENTAL  PROCEDURES 
Purification of Retroviral Proteases-AMV PR, purified from virus 
as described (12), was obtained from Molecular Genetic Resources, 
Protein designations are: MA, matrix; CA, capsid; NC, nucleocap- 
sid; PR, protease; RT, reverse transcriptase;  IN, integrase; as defined 
by Leis et al. (34). The abbreviations used are: AMV, avian myelo- 
blastosis virus; HIV, human immunodeficiency virus; RSV, Rous 
sarcoma virus; HPLC, high performance liquid chromatography. 
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Tampa, FL. Note that the RSV and AMV PRs, which differ in 
primary structure by 2 amino acids, are biochemically indistinguish- 
able and have been used interchangeably in  these studies. HIV-1 PR 
expressed in bacteria was a generous gift of Dr. Joe Giam, Case 
Western Reserve University. Purified HIV-2 PR, also expressed in 
bacteria, was a generous gift of Dr. Stuart F. J. LeGrice, Case Western 
Reserve University. 
Peptides-The peptides used in this study were synthesized and 
purified as described by Copeland and Oroszlan (13). Lyophilized 
peptides were solubilized in 1 mM 2-mercaptoethanol, and peptide 
concentrations were determined by amino acid composition analysis. 
Specificity of cleavage  was established by isolation of cleavage prod- 
ucts by reverse-phase HPLC  and determination of their amino acid 
compositions (14) or direct amino-terminal analysis of product pep- 
tides without separation (15). 
Assay of Protease Actiuity-The reaction mixture contained 100 
mM sodium phosphate, pH 5.9, 2.4 M sodium chloride (1 M sodium 
chloride was used for HIV-1 and HIV-2 PR reactions), 10-400 PM 
peptide as indicated, and 0.5-5 pg/ml protease. Reaction volumes 
were  25  pl. Reactions were initiated by the addition of protease and 
stopped by the addition of 175 p1 of 0.5 M sodium borate, pH 8.5. 
Twenty pl of 0.05% (w/v) fluorescamine was then added. The time 
of incubation was varied as indicated. HIV-1 PR was never incubated 
more than 8 min because of the instability of this enzyme, presumably 
the result of autodegradation. This is not  a problem with HIV-2 PR 
since the labile site  present  in this enzyme was mutated and can no 
longer be  processed.’ Fluorescamine reacts specifically with primary 
amines, and  its relative fluorescence intensity was determined on a 
Perkin-Elmer  Cetus Instruments LS-5B spectrofluorometer. The ex- 
citation wavelength was 386 nm, and  the emission wavelength was 
477 nm. Both excitation and emission slits were set  to 10 nm. Relative 
fluorescence intensity was converted to nmol of product using a 
standard curve described by the following equation: nmol of product 
= relative fluorescence intensity/313. The standard curve was ob- 
tained using a hexapeptide with a free amino terminus (17). The 
concentration of this peptide was determined by amino acid compo- 
sition analysis. The peptides used in this study were  designed with 
prolines at their amino termini. Since prolines do not react with 
fluorescamine, the relative fluorescence intensity represents only the 
newly formed amino  terminus  present on the carboxyl-terminal pep- 
tide fragment. Peptides containing lysine residues did not cause 
background problems since the fluorescamine reactions were carried 
out  at  pH 8.5, 2 pH  units below the pKa of the e-amino group. 
Steady-state Kinetic Analysis-Kinetic constants were determined 
using the assay described above. Concentrations of peptides ranged 
from 0.25 to 4  times the K, value. No more than 20%  of the substrate 
was  allowed to be consumed during the course of any given experi- 
ment.  Initial velocity data used to calculate kinetic constants were 
obtained from at least three experiments performed in duplicate. 
Kinetic constants were determined by a nonlinear fit of the  data  to 
the Michaelis-Menten equation using the  NFIT program (17). Cor- 
relation coefficients of the fit were greater than 0.98. The standard 
deviation of the  constants reported was no greater than 20%. 
Determination of  Ki for the RSVp2-plO Peptide Substrate-Dixon 
analysis was used to determine the K, of the RSV p2-p10 peptide 
substrate with all proteases studied (18). Ki values for the other 
peptide substrate/inhibitors were determined from IC50 values ob- 
tained from dose-response curves using the following equation (16) 
where [Et] and [SI are the protease and substrate concentrations, 
respectively, used in the assay. 
Molecular  Modeling of the RSV p2-p10 Peptide in the Active Site 
of the RSV PR-Molecular modeling used the structure of the RSV 
protease dimer with modeled flaps and substrate as described previ- 
ously (19) except that  the substrate residues were altered to those of 
the p2-p10 peptide. The side chains of the p2-p10 peptide were 
initially positioned to correspond to those in co-crystal structures of 
HIV-1 PR with inhibitors (20-24). The side chain of serine at  P1’ 
was then rotated toward the Asp-37. This moved the serine hydroxyl 
group to within hydrogen bonding distance of the side chain oxygen 
of the catalytic Asp-37. 
S. LeGrice, personal communication. 
RESULTS 
Protease Activity on Homologous Peptide Substrates-Pep- 
tide substrates of 9-12 amino acids in length, which represent 
cleavage sites in the gag and gag-pol polyprotein precursors  of 
the RSV and of the HIV-1, were synthesized. These peptides 
include the 7 amino acids, P4-P3’,  that form the minimum 
sequence required for efficient and specific cleavage by the 
retroviral protease (25, 26). These residues interact with a 
unique  array  of amino acids in the protease which  form the 
subsites S4-S3‘ of the substrate binding pocket. The P4-P3’ 
and S4-S3’ nomenclature is that established by Schecter and 
Berger (27). 
The ability of the AMV or the HIV-1 PR  to cleave peptide 
substrates derived  from their cognate polyprotein precursors 
is presented in Tables I and 11, respectively. Each protease 
was able to specifically process its respective homologous set 
of peptide substrates. The catalytic efficiency ( kCat/K,,,) of the 
AMV PR for the RSV peptide substrates varied over a 6-fold 
range for the peptides representing the CA-NCa, CA-NCb, 
NC-PR,  PR-RT, and IN-p4 cleavage sites. A peptide repre- 
senting the plO-CA  cleavage site was cleaved as efficiently as 
the NC-PR peptide. Since this peptide has proline in Pl’,  
which is  not reactive with fluorescamine, cleavage was fol- 
lowed by separation of the products by HPLC as described 
previously (17). Two other peptide substrates, MAp2 and p2- 
p10, were found to be 20-30-fold less efficiently cleaved than 
the most active RSV substrate. The low efficiency of cleavage 
of the MAp2 peptide could be explained by a much lower 
TABLE I 
Activity of the AMV PR on RSVgag  and pol peptide substrates 
Kinetic values were obtained from Michaelis-Menten plots of the 
initial velocity  uersus substrate concentration. The activity was de- 
termined using the fluorescamine assay as described under “Experi- 
mental Procedures.” The arrowhead indicates a cleavage site. 
Substrate  Sequence” K m  kcat  k d K m  
p~ min” p ~ ’  min” 
MA-p2 (P)TSCY  H GT(RR) 648 20 0.031 
* 
p2-p10 PYVG  SGLY(RR) - 6 -  0.02 
CA-NCa ( P ) M  SSAI(RR) 51 11 0.22 
CA-NCb PLIM  ANVN(RR) 17 11 0.65 
NC-PR PPAVS LAhlTM(RR) 47 21 0.45 
PR-RT (P)ATVL  TVAL(RR) 127  20 0.16 
IN-p4 PLFA  GISE(RR) 171 25 0.14 
a The parentheses indicate amino acids not part of the precursor 
polypeptide. The nomenclature of substrate positions (in brackets)  is 
illustrated with the p2-p10 peptide sequence as follows: P[P4] Y[P3] 
V[P2] G[P1] - S[Pl’]  G[P2’]  L[P3’]. 
Dash denotes too low  of a  turnover for reliable steady state kinetic 
analysis. 
TABLE I1 
Activity of the HIV-1 PR on selected HIV-1 gag and pol peptide 
substrates 
Kinetic values were obtained from Michaelis-Menten plots of the 
initial velocity  uersus substrate concentration. The activity was de- 
termined using the fluorescamine assay as described under “Experi- 
mental Procedures.” The arrowhead indicates a cleavage site. 
Substrate  Sequence“ K m  kcat %aclKm 
p~ min” p ~ ’  min” 
* 
CA-NCa (P)ARVL  AEAM(RR) 52.0 256.8 4.94 
CA-NCb (P)ATIM MQRE(RR) 127.1 894.1 7.03 
NC-p6a PGNF LQSR(R) 39.6 27.0 0.68 
NC-p6b PRQAN  FLGK(RR) 28.4 23.2 0.82 
RT-IN (P)RKIL  FLDG(RR) 37.0 170.1 4.60 
The parentheses indicate amino acids not part of the precursor 
polypeptide. 
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binding affinity for protease compared with the other sub- 
strates;  its K,,, for the AMV PR was 648 PM. In  the case of 
the least efficient substrate,  p2-pl0,  the rate of cleavage  was 
so slow that  it was only possible to determine the combined 
k,,,/K, value from the slope of the initial velocity plot. 
The HIV-1 PR specifically and rapidly cleaved peptides 
representing gag and pol polyprotein precursor cleavage sites, 
as reported previously (25, 29-31). Our steady-state kinetic 
analysis of the HIV-1 PR with five of the nine HIV-1 cleavage- 
site peptide substrates is presented in Table 11. A 10-fold 
range in  catalytic efficiencies was observed for these peptides. 
Additionally, the catalytic efficiencies were  10-20-fold higher 
than those for the AMV PR toward its homologous substrates, 
in agreement with other  reports (25, 29-31). The increased 
catalytic efficiency of the HIV-1 PR was caused by increased 
rates of catalysis; homologous substrates were bound with 
affinities  similar to those of the AMV PR with its cognate 
substrates  (Tables I and 11). In disagreement with the reports 
of others (25, 29, 30) but  in agreement with the experiments 
of Toszer et al. (32), we find that  the K, for the HIV-1 PR 
for peptide substrates  is  in the PM and  not  the mM range. 
Protease  Activity on Heterologous Peptide  Substrates-De- 
spite several reports that retroviral proteases are specific for 
their own polyprotein sequences (5), we analyzed the AMV 
and HIV-1 PRs for activity on heterologous substrates. The 
AMV PR could cleave three of the five HIV-1 peptide sub- 
strates. However, the catalytic efficiency was so low that a 
steady-state  kinetic analysis was possible for only one sub- 
strate,  RT-IN.  The K,,, was estimated at 98 PM and  the kcat at 
1.3 min”. This level of activity was considerably lower than 
that observed for the AMV PR on its homologous substrates. 
In  contrast,  the  HIV-1 PR exhibited specific processing of all 
RSV peptide substrates with the exception of p2-p10 (Table 
111). Interestingly, the catalytic efficiency (kCat/Km) of the 
HIV-1 PR for each of the RSV substrates showed the same 
variation  as observed with the AMV PR, which indicates that 
these differences are  intrinsic to  the substrates  and  not the 
protease. Nevertheless, the heterologous activity of the HIV- 
1 PR was 10-fold or more lower than  that observed for its 
comparable cognate substrates. 
Inhibition of Protease Activity  by the RSV p2-p10  Peptide 
Substrate-To determine if the reduced catalytic efficiency of 
the AMV PR on the RSV p2-p10 peptide substrate was a 
result of a reduced affinity or  a reduced rate of catalysis, we 
measured the effect of adding increasing concentrations of 
this peptide to a processing reaction that contained the RSV 
NC-PR peptide substrate. As shown in Table I, the NC-PR 
peptide is one of the most rapidly cleaved substrates for the 
AMV PR.  When added to a reaction mixture, the RSV p2- 
TABLE 111 
Activity of the  HIV-1  PR  on  RSVgag  and pol peptide  substrates 
Kinetic values were obtained from Michaelis-Menten plots of the 
initial velocity versus substrate  concentration. The activity was de- 
termined using the fluorescamine assay as described under “Experi- 
mental Procedures.” The arrowhead indicates a cleavage site. 
Substrate Sequence” Km kcat k J K m  
p~ min” p ~ ’  rnin” 
t 
MA-p2 (P)TSCY HCGT(RR) 250  31.2  0.12 
p2-plO PYVG SGLY(RR) ND”  NDb 
CA-NCa (P)AAAM SSAI(RR) 15 13.5 0.9 
PLIM ANVN(RR) 25  35.3  1.4 
PPAVS LA”(RR) 16 43.8  2.7 
CA-NCb 
NC-PR 
PR-RT (P)ATVL TVAL(RR) 224  29.9  0.13 
IN-p4 PLFA GISE(RR) 167 12.3 0.07 
The parentheses  indicate  amino acids not  part of the precursor 
ND, cleavage not detected. 
polypeptide. 
p10 peptide inhibited the AMV PR cleavage of the RSV NC- 
PR peptide substrate (Fig. 1) with a Ki of 20 PM (Table IV). 
The inhibition was competitive, based on the Dixon plot 
shown in Fig. 2, where the extrapolated lines for the three 
concentrations of NC-PR peptide substrate  tested intersected 
above the x axis (18). 
A control inhibition study using the RSV  plO-CA peptide 
substrate is presented in Fig. 1. This peptide binds with 
similar affinity and is processed by the AMV PR  at about the 
same rate as the RSV NC-PR peptide substrate. However, 
cleavage of this peptide cannot be  followed  by the fluoresca- 
0 1 0 0  2 0 0  3 0 0  4 0 0  
[Inhibitory Peptide] (kM) 
FIG. 1. Inhibition of the AMV PR by the p2-p10 cleavage- 
site peptide substrate. The NC-PR peptide substrate (200 p ~ )  was 
incubated with the AMV PR (50 ng) and different concentrations of 
the RSV p2-p10 (U), RSV  plO-CA (e), RSV  MA-p2 (m), or  Moloney 
leukemia virus CA-NC (0) peptide substrates. The extent of NC-PR 
cleavage was determined as described under “Experimental Proce- 
dures.” 
TABLE IV 
Inhibition of AMV  PR cleavage of the RSV  NC-PR  peptide  substrate 
by wild type or RSVp2-plOpeptide analogues 
Inhibitory peptide“ Ki 
” 
20 PYVG SGLY(RR) 
PYVG TGLY(RR) 12.5 
PYVG SSLY(RR) 22.7 
P Y E  SSLY(RR) 5 
PYVG SIjLY(RR) 20.1 
PYVG SGTY(RR) 8.9 
PYVG SGAY(RR) 27.1 
w 
Ac-SGLY(RR) >200 
PYVL  SGLY(RR) 6 
PYWj SGLY(RR) 3.3 
P-F SGLY(RR) 0.5 
P L Y  SGLY(RR) 0.5 
The RSV  p2-pIO peptide was  modified in the P4-P3’ positions 
as indicated by the underlined letter(s).  Parentheses indicate amino 
acids not  present in the RSV precursor polypeptide. The arrowhead 
indicates a cleavage site. 
.” 
-50 0 5 0  100 150 200 
[ P ~ - P ~ O I  ( W )  
FIG. 2. Dixon analysis of the p2-p10 peptide inhibition of 
the AMV PR. The AMV PR (50 ng) was incubated as described 
under “Experimental Procedures” with three  concentrations of the 
NC-PR peptide substrate as follows:  50 pM (El), 100 pM (e), and 200 
p~ (m), and p2-pIO peptide in concentrations indicated. 
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mine assay since proline is present  in the P1’ position. As 
expected, the addition of this peptide to a reaction mixture 
containing the  NC-PR  substrate resulted in 50% inhibition 
of NC-PR cleavage, as measured by fluorescence, when equi- 
molar amounts of the two peptide substrates were present. 
Also included in Fig. 1 are  the results when the RSV  MA- 
p2 peptide substrate was added to  the reaction. This substrate 
was  cleaved by the AMV PR  at a very low efficiency because 
of its high K,; less than 5% cleavage  was observed under the 
conditions used in this experiment. The addition of this 
peptide had  little effect on the cleavage of the NC-PR sub- 
strate.  Similar  results were obtained with the Moloney leu- 
kemia virus CA-NC peptide substrate (Fig. 1). 
Cleavage of the RSV p2-p10 peptide by the HIV-1 PR was 
not detected (Table 111). We therefore tested whether the 
RSV p2-p10 peptide could inhibit the cleavage of a HIV 
peptide (NC-p6a) by either the HIV-1 or HIV-2 PRs.  These 
results are presented in Table V. The RSV p2-p10 peptide 
was found to be an effective inhibitor of these enzymes, with 
K, values of 18 and 5 p~ for the HIV-1 and HIV-2 PRs, 
respectively. Similar Ki values were obtained with the HIV-1 
PR using the RSV NC-PR peptide substrate (Table V). 
Therefore, the RSV p2-p10 peptide is an inhibitor of all  three 
of the retroviral  proteases tested. 
Modeling of the RSVp2-plO  Peptide  Substrate in the Active 
Site of the AMV PR-To evaluate the potential  interactions 
between residues of the RSV p2-p10 peptide substrate and 
the enzyme and to understand the basis of its inhibitory 
activity, we examined a model of the RSV PR (19) with the 
p2-p10 peptide substrate (Fig. 3A). This model is derived from 
the  structure of an inhibitor bound to  the HIV-1 PR (20) (see 
Fig. 3B).  In  the RSV model it was possible to rotate the side 
chain of the P1’ serine in the p2-plO peptide to allow forma- 
tion of a hydrogen bond between its side chain OH and  the 
side chain 6 oxygen of one of the two catalytic  aspartates (Fig. 
3A). We propose that formation of such an interaction would 
disrupt the electrostatic charge distribution required for ca- 
talysis. 
Analysis of RSV p2-p10 Peptide  Substrates Modified at the 
PI’ Position-To investigate the putative inhibitory role of 
the serine in the  P1’ position, we synthesized a series of p2- 
p10 peptide analogues in which alanine, leucine, or  threonine 
replaced serine. The  first two substitutions lack a hydroxyl 
group, whereas the threonine, which has  a hydroxyl, contains 
a methyl group extension on the p carbon. As shown in Table 
VI, substitution of the P1’ serine with an alanine  or leucine 
allowed  cleavage of the p2-p10 analogue by the AMV PR with 
an efficiency comparable to  that of the NC-PR peptide sub- 
strate.  Concomitant with this activation,  both of these P1’- 
modified p2-p10 peptides exhibited decreased effectiveness as 
competitive inhibitors. In contrast, the substitution of threo- 
nine did not increase the rate of cleavage of the p2-p10 
peptide. Instead, it improved its ability to  act  as  an inhibitor 
(Table IV). These  results  are  consistent with the hypothesis 
TABLE V 
Inhibition of the  HIV-1 or 2 PRs by the wild-type and RSVp2-plO 
peptide analogues 
PR Substrate  Inhibitory  peptide” K.  
P M  
HIV-1  RSV NC-PR P W G  SGLY(RR) 8.3 
t 
P W L  SGLY(RR) 13.3 
HIV NC-p6a P W G  SGLY  (RR) 18 
HIV-2  I  NC-p6a P W G  SGLY(RR) 5 
The RSV p2-p10 peptide was modified at the P1 position as 
indicated by the underlined letter. The arrowhead indicates a cleavage 
site. 
that  the inhibitory properties of the p2-p10 peptide are related 
to the presence of a hydroxyl group on a residue which 
occupies the P1’ position. 
Analysis of RSV p2-p10 Peptide Substrates Modified at the 
PI and P2’ Positions-Examination of the various RSV  gag 
and p o l  cleavage sites indicates that  the CA-NCa and  PR-RT 
have serine  and  threonine, respectively, in the P1’ position 
and  that NC-PR has serine in P1, yet these peptide substrates 
are efficiently cleaved  by the AMV PR (Table  I). The p2-p10 
sequence differs from these by the presence of glycine residues 
in P1 and P2’. Glycine,  which lacks a side chain, may provide 
greater conformational flexibility for the P1 ’ serine and facil- 
itate formation of the hydrogen bond between the serine OH 
and  the nearby catalytic aspartic acid  residue. If this hypoth- 
esis is correct, then substitution of small nonpolar amino 
acids, such as  alanine or valine, in P2’ might hinder formation 
of the putative Asp-Ser interaction by binding more tightly 
to  the relatively hydrophobic S2’ enzyme subsite and thereby 
restrict the rotational freedom of the P1’ serine. This is 
predicted to activate the p2-p10 peptide for cleavage. Our 
results (Table VI) show that introduction of either  alanine or 
valine in P2’ resulted in cleavage of the p2-p10 peptide 
analogues by the AMV PR, with efficiencies comparable to 
that observed with the NC-PR peptide substrate  (Table VI). 
Concomitantly, there was a decrease in effectiveness to  act  as 
inhibitors  (data  not shown). In  contrast, the substitution in 
P2’ of more polar amino acid residues, such as serine or 
asparagine, maintained the inhibitory properties of the  ana- 
logues (Table IV) and did not  activate  them for cleavage. The 
polar residues in P2’ would be predicted to “weaken” the 
interaction between the P2’ position of the substrate  and the 
nonpolar S2’ protease subsite and thus result in more rota- 
tional freedom for the serine in P1’ to form the hydrogen 
bond with Asp-37. 
We also tested whether the glycine residue in P1 was 
required for the inhibitory properties of the p2-p10 peptide. 
In  contrast  to  the alanine or valine substitutions  in P2‘, the 
substitution of leucine at P1 produced an effective inhibitor 
with a K, of 6 p~ (Table IV). This result is not totally 
surprising since the S1 enzyme subsite is known to accom- 
modate large amino acid residues readily (19). A possible 
steric role for the glycine in P1, however, could not be ex- 
cluded, since this peptide contained the glycine in P2’. This 
possibility was eliminated by the peptide in Table IV in which 
the glycine residues in P1 and P2’ were replaced with leucine 
and serine, respectively. This peptide proved to be an inhibitor 
with a Ki of 5 pM. 
To determine if the serine at P1’ and  the glycine at P2’ 
were both necessary and sufficient to confer upon a peptide 
the inhibitory properties observed for the p2-p10 peptide, we 
constructed  a RSV CA-NCa peptide analogue with a glycine 
residue in P2’. The wild type CA-NCa peptide contains me- 
thionine, serine, and serine residues, in the P1, Pl’, and P2’ 
positions, respectively, and is efficiently cleaved by the AMV 
PR (Table  I).  Substituting glycine for serine in P2’ resulted 
in a 90% reduction in its  rate of cleavage.  However, mixing 
this analogue with the NC-PR substrate had little effect upon 
cleavage of the  latter (Table VII). Similar results were ob- 
tained with a peptide corresponding to  the sequence PASVL- 
SGGERR which is found in the amino terminus of the HIV- 
1 and Moloney leukemia virus MA proteins  (data  not shown). 
Taken together, these results indicate that the serine and 
glycine residues at P1’ and  P2’ positions, respectively, of the 
wild type p2-plO peptide are necessary but  not sufficient for 
its inhibitory activity. 
Analysis of RSVp2-plO Peptide Substrates Modified at the 
Pl-P4 Positions-An additional element that appears to in- 
fluence the inhibitory properties of the p2-p10 peptide is  its 
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FIG. 3. Panel A ,  stereo view of P1-P1’ of the p2-plO peptide modeled in the active site of the RSV PR. The p2-plO peptide has Gly- 
[CONHI-Ser at P1-P1’ and is denoted by the thick lines. The RSV PR active site residues Asp-37, Ser-38, Gly-39, and 37‘-39’ from the other 
subunit (thin lines) are shown in an orientation similar to  that shown in panel B. The  P1’ serine OH side chain has been rotated, as described 
under  “Experimental Procedures,” so that a hydrogen bond (dashed  line) is possible with the 6 oxygen of Asp-37. Panel B,  stereo view  of PI- 
P1’ and the catalytic triplets of HIV-1 PR from the crystal structure with inhibitor U85548e (2). P1-P1’ of the inhibitor are Leu- 
ILICH(OH)CH21-Val, and residues ASR-25, Thr-26, and Gls-27 and 25’-27‘  from the two subunits  in the protease dimer are shown. Hydrogen ~. 
bond interactions are indicated by d&hed.lines. 
TABLE VI 
Activity of the AMV  PR on the RSVp2-plOpeptide  with amino acid 
substitutions in the PI‘ and P2‘ positions 
Sequence” K m  k,, L J K m  
P M  min” p M “  min” 
PYVG SGLY(RR) 0.02 
PYVG AGLY(RR) 19.2  3.4 0.18 
PYVG &GLY(RR) 22.9  7.5  0.33 
PYVG SGY(RR) 13.5  9.8  0.73 
PYVG S&Y(RR) 9.8  11.5  1.17 
w 
“The RSV p2-p10 peptide sequence was modified at  the  P1’  and 
P2’ positions as indicated by the underlined letters. All of these 
substrates were cleaved at  the correct site  as established by amino- 
terminal analysis of the products (data  not shown). The arrowhead 
indicates  a cleavage site. 
TABLE VI1 
Inhibition of AMV  PR cleavage of the RSV  NC-PRpeptide substrate 
by RSVp2-plO and CA-NCa hybrid peptide analogues 




PYVG SSAI(RR) 56.0 
PwL_ SSAI(RR) 33.3 
PYVG SCAI(RR) 20.5 
CA-plO (P)AAAM SGLY(RR) >200 
(P)AAAM SGAI(RR) >200 
(P)AAAM SGL&(RR) >200 
a Hybrid peptide analogues combining the amino- and carboxyl- 
terminal  portions of the RSV p2-plO and CA-NCa cleavage sites were 
prepared as indicated under  “Experimental Procedures.” Amino acids 
which differ from the parental hybrid are underlined. None of the 
peptide analogues was cleaved efficiently by the AMV PR. The 
arrowhead indicates  a cleavage site. 
affinity for protease mediated by the  Pl-P4 amino acids. This 
is inferred from the fact that  the carboxyl-terminal portion 
of the p2-p10 peptide, which contains the P1’ serine, has a K; 
of more than 200 ~ L M  (Table IV). To investigate the role of 
the P1-P4 amino acids in binding the peptide to  the protease, 
leucine, tryptophan, phenylalanine, or histidine was intro- 
duced in  the P1, P3, or P4 position of the p2-p10 substrate  as 
indicated in Table IV. Substitution of leucine or  tryptophan 
in P1 resulted in a 3- and g-fold, respectively, decrease in the 
Ki of the p2-p10 analogue. Furthermore, combining the  sub- 
stitutions of phenylalanine in  P3 with the tryptophan in P1 
produced a 40-fold decrease in the K,. The additional substi- 
tution of histidine for proline in P4 had little effect (Table 
IV). These results directly parallel those from independent 
experiments in which the same amino acids were introduced 
into comparable positions of the NC-PR substrate (19). 
Steady-state kinetic analysis of these substrates indicated 
that substitution of leucine or tryptophan  into P1 or phenyl- 
alanine  into P3 resulted in a 2.4-, 4.4-, and 6.3-fold decrease, 
respectively, in the K,,, of these NC-PR analogues for the 
AMV PR (19). Previous studies have shown that  the enzyme 
subsites act independently in recognition of substrate (19). 
Therefore, combining the effect of substituting  tryptophan in 
P1 with phenylalanine in P3, one calculates a 28-fold additive 
decrease in the K,,, for the NC-PR peptide. Substitution of 
histidine in  P4 produced a 1.5-fold increase in  the K ,  for the 
NC-PR peptide (data  not shown). Thus, amino acids in the 
Pl-P4 positions predicted to improve the binding affinity of 
the peptide to protease showed increased effectiveness of p2- 
p10 analogues to act  as inhibitors. 
The importance of the Pl-P4 substrate positions as a 
docking element is  further  illustrated by analysis of the  chi- 
meric peptides which combined the amino- and carboxyl- 
terminal  portions of the CA-NCa and p2-p10 peptides (Table 
VII). The chimeric p2-NC peptides, which had the Pl-P4 
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residues of the p2-p10 peptide, were effective inhibitors of the 
AMV PR, whereas the CA-plO peptides were not. A docking 
role for the P1 substrate position is also observed with the 
HIV-1 PR. When leucine is substituted  into the P1 position 
of the RSV NC-PR and p2-p10 peptides, respectively, it 
resulted in an increase in the K,,, for the former (19) and K; 
for the  latter (Table V). 
Analysis of RSVp2-plO  Peptide  Substrates Modified at the 
P2‘ and P3‘ Positions-Although there is a good correlation 
between decreasing the Ki of p2-p10 peptide analogues and 
decreasing the K,,, of comparable NC-PR peptide analogues 
for amino acid substitutions  in Pl-P4,  this relationship does 
not hold for placing substitutions in Pl’-P3’. For  instance, 
substitution of serine  in P2’ or tyrosine in P3’ of the  NC-PR 
peptide resulted in increases of greater than 7- and 1.2-fold, 
respectively, in  the K,,, with the AMV protea~e.~ Yet these 
same substitutions  in the p2-p10 peptide produced inhibitors 
with decreased Ki values (Table IV). Thus,  the P2’ and P3‘ 
amino acids do not serve the same role of the  Pl-P4 amino 
acids for binding the peptide to  the protease substrate binding 
pocket. Instead,  their  function is more related to providing 
rotational freedom for the serine in Pl’. In the case of P3’, 
which  is adjacent to P1’ in the substrate binding pocket, the 
presence of larger amino acids may prevent tight  interactions 
between the protease and  the peptide, thereby providing ad- 
ditional  rotational freedom for the serine in Pl’. Results with 
the substitution of tyrosine for leucine at P3’, which decreased 
the Ki of the p2-p10 analogue by more than %fold, are 
consistent with this  interpretation.  Introduction of a smaller 
amino acid, alanine, at  the same position resulted in a small 
increase in the Ki (Table IV). 
DISCUSSION 
We have studied the activity of the AMV and  HIV-1 PRs 
on peptide substrates which represent cleavage sites in the 
RSV and HIV-1 gag and gag-pol polyprotein precursors. The 
kinetic properties of the HIV-1 peptide substrates reported 
here are similar to those published previously (32). Analysis 
of the catalytic efficiencies of the AMV protease on its cognate 
peptide substrates indicates that, for the most part,  there  are 
only small kinetic differences between the various cleavage- 
site peptide substrates with the exception of those represent- 
ing the MA-p2 and p2-p10 cleavage sites. In all cases, the 
sites of cleavage of the peptide substrates were independently 
verified. Strop  et al. (28) have reported different results for 
cleavage of larger peptides containing some of the RSV cleav- 
age sites. These  results may not be directly comparable, since 
these larger peptides have solubility problems. Additionally, 
a steady-state kinetic analysis was not completed, and the 
sites of cleavage  were not established in  these studies. 
In  the case of RSV, it has been suggested that maturation 
of the gag and gag-pol polyprotein precursors occurs with an 
ordered release of mature proteins (5). Our study suggests 
that the slow processing observed i n  vivo of the amino- 
terminal  proteins of the gag precursor may  be related in part 
to the low efficiency with which the MA-p2 and p2-p10 
cleavage sites  are processed by protease. This hypothesis is 
further  supported by the observation that substitution of the 
7 amino acids of the slow  MA-p2  cleavage site with those of 
the fast  NC-PR cleavage site in vivo resulted in a greater than 
10-fold increase in the  rate of processing at this site.4 How- 
ever, apparent differences in catalytic efficiency of protease 
in vivo with the  other cleavage sites  in the gag and gag-pol 
C. E. Cameron, B. Grinde, J. Jentoft, J. Leis, I. T. Weber, and A. 
C. E. Cameron, H. Burstein, A. M. Skalka, and J. Leis, unpub- 
Wlodawer, unpublished observations. 
lished observations. 
polyproteins, suggested by the order of appearance of inter- 
mediates, would  be influenced more by the three-dimensional 
folding of these polyproteins and the accessibility of the 
different cleavage sites. 
A comparison of the activity of the retroviral proteases on 
heterologous substrates suggests that the AMV enzyme is 
more stringent than HIV-1 in recognition of cleavage sites. 
The AMV PR has barely detectable activity on the HIV-1 
peptide substrates tested. In  contrast, the HIV-1 PR cleaved 
all of the RSV peptide substrates with efficiencies equivalent 
to those of AMV PR.  The only exception was the RSV p2- 
p10 substrate which neither the HIV-1 nor the HIV-2 PRs 
were able to cleave. This peptide is  cleaved  by the AMV PR, 
but at a low efficiency  because of a low catalytic rate. However, 
it binds reasonably well to  the protease and  acts  as  a compet- 
itive inhibitor of the AMV as well as  the  HIV-1  and HIV-2 
PRs. 
Analysis of several co-crystal structures of HIV-1 PR with 
different inhibitors (20-24) has shown that peptidic inhibitors 
bind in an extended @-conformation between the active site 
and  the two symmetrically related flexible flaps. There is a 
series of @-sheet-like hydrogen bonds between the carbonyl 
and amide groups of the inhibitor  and protease residues that 
connect the flaps, the inhibitor, and residues 27-29 (HIV-1) 
at  the active site which provide binding energy for a peptide 
or part of a  protein  to bind to protease. In addition, each side 
chain of the inhibitor lies in a corresponding subsite formed 
by amino acid residues of the enzyme. These alternate on 
either side of the main chain of the inhibitor and provide 
specific interactions with substrate side chains. The inhibitor 
side chains  protrude  into the subsites approximately perpen- 
dicular to  the plane of the @-sheet formed by the substrate 
backbone. This means that  the interactions of the side chains 
are largely independent of the hydrogen bond interactions to 
the main chain. Computer modeling and comparison with 
kinetic measurements have suggested that substrate peptides 
bind to HIV-1 (31) and RSV (19) PRs in a manner resembling 
the inhibitors in the crystal  structures of HIV-1  PR. 
Many of the more  effective inhibitors of retroviral proteases 
are  transition  state analogues and  contain  a nonhydrolyzable 
isostere instead of the scissile bond between P1 and Pl’. 
Peptidic compounds with hydroxyethylene have a hydroxyl 
group (OH) in the place of the carbonyl oxygen (C=O) of the 
scissile peptide bond, as  illustrated by the co-crystal structures 
of HIV-1 PR with these  inhibitors (20-23). This is consistent 
with the reaction mechanism deduced by Hyland et al. (33). 
In these  inhibitors, which include acetyl-pepstatin (22), the 
hydroxyl group interacts with the carboxylates of the two 
catalytic aspartic acids (Asp-25 in HIV-1 PR) and may  form 
several hydrogen bonds, as shown in Fig. 3B for the HIV-1 
PR inhibitor  structure of Jaskolski et al. (20). 
We propose that the inhibitory p2-p10 peptide acts by 
formation of a hydrogen bond between the hydroxyl side chain 
of the serine at P1’ and  the carboxylate oxygen of the closest 
catalytic aspartate.  This is shown in  the structural model of 
the complex between the RSV PR and the p2-p10 peptide in 
Fig. 3A. This  interaction  can be made  by a simple rotation of 
the serine side chain which is a minor adjustment of the 
conformation. We propose that  this hydrogen bond interac- 
tion  alters the protonation  state of the 2 catalytic aspartates. 
These aspartates  participate in a conserved network of hydro- 
gen bond interactions that connect the two halves of the 
active site (Asp-Ser-Gly from each subunit of the RSV pro- 
tease dimer). This network must stabilize the correct confor- 
mation and electronic state necessary for proteolysis to occur. 
Any interference with these interactions would be expected 
to reduce the efficiency of catalysis. 
Amino  acid substitutions of the p2-p10 peptide have shown 
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that  its inhibitory effect depends upon tight binding of the 
peptide to  the  substrate binding pocket mediated by residues 
at P4-P1. Substitution of residues in the Pl-P4 positions 
that are predicted to increase the affinity of the p2-plO peptide 
for the protease produce more effective inhibitors. Combining 
the substitution of tryptophan  and phenylalanine in P1 and 
P3, respectively, resulted in an additive effect on the Ki 
producing a nM inhibitor. This result confirms the relative 
independence of the different enzyme subsites  in recognition 
of substrate described previously (19). 
The final element for inhibition is the requirement for a 
glycine or small polar residue, such as  serine or asparagine, 
at P2’ and/or a larger amino acid residue at P3’. A small 
hydrophobic residue at P3’ reduces the inhibitory effect. We 
propose that  this is due partly to a  tight fit of the binding site 
around the smaller residues, which  would restrict the rotation 
of serine at Pl’. In  contrast, large hydrophobic residues at 
P3’ would tend to expand the binding sites and have the 
opposite effect on the rotation of the P1’ serine. The side 
chain of P3’ is adjacent to P1’ because of the alternating p- 
like conformation, so the size of the P3’ side chains may 
directly effect the size of the S1’ subsite. The effect of the 
P2’ residue is more complex, since small hydrophobic residues 
such as valine and alanine position the p2-p10 peptide for 
substrate cleavage by providing tight binding to the S2‘ 
enzyme subsite. This  is proposed to restrict the rotation of 
the PI’ serine. In  contrast,  substitution of glycine, serine, or 
asparagine at P2’ resulted in inhibitors. Glycine at P2’ is 
most effective as  an inhibitor, even when P3’ contains small 
residues. This is because glycine lacks a side chain and allows 
easier rotation of serine at Pl’. Serine and asparagine at P2’ 
also form inhibitory p2-p10 analogues but  are more effective 
if a large hydrophobic residue is present at P3’. The polar 
side chains of serine and asparagine are predicted to bend 
toward the polar environment formed by the main chain 
amide and carbonyl groups. This would leave the S2’ subsite 
of protease  partly  vacant, providing the flexibility necessary 
for the P1‘ serine hydroxyl to rotate  into the conformation 
required for inhibition. 
The mechanism of inhibition of the HIV-1 PR by the p2- 
p10 peptide is more complicated. In  contrast  to results with 
the AMV PR, none of the p2-p10 peptide analogues, including 
leucine or alanine in P1’ or alanine in P2’ positions, was 
found to activate  this peptide as  a  substrate.  This indicates 
that there  are some distinct,  but  subtle, differences between 
the HIV-1 and the AMV PRs. Structural studies with the 
HIV-1 PR and p2-p10 analogues may clarify this issue. 
Is  there  any biological significance to having an inhibitory 
sequence in cis in  the RSV Pr76gag? It is known that  the viral 
precursor polypeptide is not normally processed until  the virus 
buds from the cell surface. One can speculate on putative 
mechanisms that would delay activation of the protease. One 
possibility would be that  the p2-p10 inhibitory sequence on 
one of the precursors binds to  the active site of a protease 
precursor homodimer. Upon reaching the site of viral assem- 
bly at  the cell membrane, cleavage and/or displacement of the 
“inhibitory” sequence may lead to activation of protease. 
Alternatively, one can visualize regulating protease precursor 
homodimer formation directly through different conforma- 
tions  or aggregation states of the associated precursor mole- 
cules or kinetically by the low turnover number of the pro- 
tease. Since the RSV PR is relatively inefficient, only a weak 
inhibitory effect may be needed. Once the polyproteins are 
enclosed in the viral particles, however, the higher concentra- 
tion of protease will increase the effectiveness of cleavage and 
subsequent maturation. The possibility that  the p2-p10 se- 
quence is involved in control of protease activation can be 
tested by introducing mutations  into  this sequence and  deter- 
mining the effects on processing of precursor polypeptides in 
vivo. 
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